» Articles » PMID: 35441664

A New Prediction Model for Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy

Abstract

Aims: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients.

Methods And Results: Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44-9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73-0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92-0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.3% reduction of ICD placements with the same proportion of protected patients (P < 0.001).

Conclusion: Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).

Citing Articles

Risk stratification in arrhythmogenic cardiomyopathy: scoring or personalized medicine?.

Martini M, Rigato I, Masini M, De Lazzari M, Mattesi G, Pilichou K Eur Heart J Suppl. 2025; 27(Suppl 1):i36-i39.

PMID: 39980766 PMC: 11836712. DOI: 10.1093/eurheartjsupp/suae098.


Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants.

Gigli M, Stolfo D, Barbati G, Graw S, Chen S, Merlo M JAMA Cardiol. 2025; .

PMID: 39937464 PMC: 11822610. DOI: 10.1001/jamacardio.2024.5543.


Implantable Cardioverter Defibrillator for Primary Prevention in Children With Arrhythmogenic Right Ventricular Cardiomyopathy: A Case Series.

Nagashima-Otsuki A, Ishii T, Yamaguchi Y, Hosokawa S, Doi S Cureus. 2025; 17(1):e77253.

PMID: 39931627 PMC: 11810138. DOI: 10.7759/cureus.77253.


A new prediction model for sustained ventricular tachycardia in arrhythmogenic cardiomyopathy.

Zhang B, Xie X, Yu J, Wu Y, Zhou J, Li X Front Cardiovasc Med. 2024; 11:1477931.

PMID: 39736878 PMC: 11683097. DOI: 10.3389/fcvm.2024.1477931.


Advances in Cardiac Imaging and Genetic Testing for Diagnosis and Risk Stratification in Cardiomyopathies: 2024 Update.

Gasior T J Clin Med. 2024; 13(23).

PMID: 39685624 PMC: 11642006. DOI: 10.3390/jcm13237166.


References
1.
Corrado D, Wichter T, Link M, Hauer R, Marchlinski F, Anastasakis A . Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J. 2015; 36(46):3227-37. PMC: 4670964. DOI: 10.1093/eurheartj/ehv162. View

2.
Orgeron G, Te Riele A, Tichnell C, Wang W, Murray B, Bhonsale A . Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circ Arrhythm Electrophysiol. 2018; 11(2):e005593. DOI: 10.1161/CIRCEP.117.005593. View

3.
Bhonsale A, James C, Tichnell C, Murray B, Gagarin D, Philips B . Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011; 58(14):1485-96. DOI: 10.1016/j.jacc.2011.06.043. View

4.
Bosman L, Sammani A, James C, Cadrin-Tourigny J, Calkins H, van Tintelen J . Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm. 2018; 15(7):1097-1107. DOI: 10.1016/j.hrthm.2018.01.031. View

5.
Buuren S, Boshuizen H, Knook D . Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999; 18(6):681-94. DOI: 10.1002/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r. View